Recently,
magnetic skyrmion has attracted much attention due to its potential
application in racetrack memory and other nanodevices. In bulk chiral
magnets with non-centrosymmetric crystal structures, skyrmion lattice
phase has been extensively observed. However, in film or multilayers
with interfacial Dzyaloshinskii–Moriya interaction, individual
skyrmion is often observed. Here, we report a short-ordered skyrmion
lattice observed in [Ta(5.0 nm)/CoFeB(1.5 nm)/MgO(1.0 nm)]15 multilayer in a remnant state. The structure, stabilization, and
reversal of these skyrmions are discussed. Applying a slightly tilted
in-plane magnetic field caused reversal of the skyrmion lattice. This
reversal came from disappearance of skyrmions and nucleation of new
skyrmions in the interstitial regions of the lattice. Also, we investigated
how the skyrmion lattice depended on the CoFeB thickness. Our findings
provide a pathway to stabilize and reverse the skyrmions in multilayers
films.
The stabilization of skyrmion bubbles in [Ta(tTa)/CoFeB(1.1 nm)/MgO(1.0 nm)]15/Ta(2.0 nm) magnetic multilayers with perpendicular magnetic anisotropy is investigated. The size of the skyrmion bubbles can be controlled by tuning the Ta interlayer thickness. Because the perpendicular anisotropy constant is large in samples with a thin Ta interlayer, we can observe nanoscale skyrmion bubbles in our system. This finding provides a means to control the skyrmion size without using an external magnetic field. Moreover, we found that skyrmion bubbles can be created by a magnetic tip and subsequently be deleted. Our novel findings provide insight into skyrmion-based spintronic devices.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.